HUE054473T2 - Eljárás HIV-integráz inhibitor hatású vegyületek elõállítására - Google Patents
Eljárás HIV-integráz inhibitor hatású vegyületek elõállításáraInfo
- Publication number
- HUE054473T2 HUE054473T2 HUE18203589A HUE18203589A HUE054473T2 HU E054473 T2 HUE054473 T2 HU E054473T2 HU E18203589 A HUE18203589 A HU E18203589A HU E18203589 A HUE18203589 A HU E18203589A HU E054473 T2 HUE054473 T2 HU E054473T2
- Authority
- HU
- Hungary
- Prior art keywords
- inhivitory
- activity
- hiv integrase
- producing compounds
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Heat Sensitive Colour Forming Recording (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010175899 | 2010-08-05 | ||
| JP2010277713 | 2010-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE054473T2 true HUE054473T2 (hu) | 2021-09-28 |
Family
ID=45559561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE18203589A HUE054473T2 (hu) | 2010-08-05 | 2011-08-04 | Eljárás HIV-integráz inhibitor hatású vegyületek elõállítására |
Country Status (18)
| Country | Link |
|---|---|
| US (8) | US20140011995A1 (hu) |
| EP (3) | EP3127908B1 (hu) |
| JP (1) | JP5636054B2 (hu) |
| CN (3) | CN103154004B (hu) |
| BR (1) | BR112013002461A2 (hu) |
| CY (1) | CY1124582T1 (hu) |
| DK (1) | DK3456721T3 (hu) |
| ES (3) | ES2608377T3 (hu) |
| HR (1) | HRP20210748T1 (hu) |
| HU (1) | HUE054473T2 (hu) |
| LT (1) | LT3456721T (hu) |
| PL (1) | PL3456721T3 (hu) |
| PT (3) | PT2602260T (hu) |
| RS (1) | RS61796B1 (hu) |
| SG (1) | SG187683A1 (hu) |
| SI (1) | SI3456721T1 (hu) |
| TW (1) | TWI510451B (hu) |
| WO (1) | WO2012018065A1 (hu) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101700267B1 (ko) | 2008-07-25 | 2017-01-26 | 비이브 헬쓰케어 컴퍼니 | 화합물 |
| MX2011006241A (es) | 2008-12-11 | 2011-06-28 | Shionogi & Co | Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios. |
| PT2376453T (pt) | 2008-12-11 | 2020-01-14 | Shionogi & Co | Processos e intermediários para inibidores carbamoilpiridona da integrase de vih |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Ｖｉｉｖ醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
| CN103154004B (zh) * | 2010-08-05 | 2016-07-06 | 盐野义制药株式会社 | 具有hiv整合酶抑制活性的化合物的制造方法 |
| PL2822954T3 (pl) | 2012-12-21 | 2016-09-30 | Policykliczne związki karbamoilopirydonu i ich farmaceutyczne zastosowanie | |
| NO2865735T3 (hu) | 2013-07-12 | 2018-07-21 | ||
| ES2859102T3 (es) | 2013-07-12 | 2021-10-01 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH |
| IN2014CH00247A (hu) | 2014-01-21 | 2015-08-14 | Laurus Labs Private Ltd | |
| CN105121409B (zh) * | 2014-03-19 | 2017-05-24 | 杭州普晒医药科技有限公司 | 德罗格韦钠盐的晶型及其制备方法 |
| TWI677489B (zh) * | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| NO2717902T3 (hu) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| EP3229804B1 (en) | 2014-12-09 | 2020-05-06 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
| WO2016092527A1 (en) * | 2014-12-12 | 2016-06-16 | Sun Pharmaceutical Industries Limited | A process for the preparation of dolutegravir |
| TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| CN104557686A (zh) * | 2014-12-29 | 2015-04-29 | 徐俊烨 | 一种吡啶酮类化合物的合成方法 |
| EP3045461A1 (en) * | 2015-01-16 | 2016-07-20 | LEK Pharmaceuticals d.d. | Processes for preparing dolutegravir and analogues thereof |
| EP3736274A1 (en) | 2015-04-02 | 2020-11-11 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| JP2019501163A (ja) * | 2015-12-21 | 2019-01-17 | ルピン・リミテッド | Ｈｉｖインテグラーゼ阻害剤の製造方法 |
| US11117904B2 (en) | 2016-06-23 | 2021-09-14 | Viiv Healthcare Company | Compositions and methods for the delivery of therapeutics |
| JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| ZA201803942B (en) * | 2017-06-13 | 2021-05-26 | Cipla Ltd | Novel processes for preparation of integrase inhibitor |
| US11286262B2 (en) * | 2017-10-06 | 2022-03-29 | Shionogi & Co., Ltd. | Stereoselective process for preparing substituted polycyclic pyridone derivatives |
| CN108101838B (zh) * | 2017-12-18 | 2020-10-20 | 安徽唯诗杨信息科技有限公司 | 一种度鲁特韦中间体的合成方法及其有关物质检测方法 |
| ES2975333T3 (es) | 2018-07-12 | 2024-07-04 | Laurus Labs Ltd | Un proceso para la purificación de derivados policíclicos de carbamoilpiridona protegidos |
| EP4234560A3 (en) | 2018-10-22 | 2023-09-13 | Board of Regents of the University of Nebraska | Antiviral prodrugs and nanoformulations thereof |
| SI3938047T1 (sl) | 2019-03-22 | 2022-10-28 | Gilead Sciences, Inc. | Premoščene triciklične karbamoilpiridonske spojine in njihova farmacevtska uporaba |
| CN110128448A (zh) * | 2019-05-22 | 2019-08-16 | 博诺康源(北京)药业科技有限公司 | 一种度鲁特韦原料及中间体中非对映异构体杂质的合成方法 |
| CN110396099A (zh) * | 2019-05-22 | 2019-11-01 | 博诺康源(北京)药业科技有限公司 | 一种度鲁特韦原料中非对映异构体杂质的合成方法 |
| US20200398978A1 (en) | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
| US11248005B2 (en) | 2019-07-08 | 2022-02-15 | Lupin Limited | Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor |
| CN110698473B (zh) * | 2019-10-08 | 2020-12-18 | 浙江大学 | 哌嗪酮并羟基吡啶酮-5-羧基类化合物及制备和应用 |
| PE20221569A1 (es) | 2020-02-24 | 2022-10-06 | Gilead Sciences Inc | Compuestos tetraciclicos para el tratamiento de infecciones por vih |
| CN111620891B (zh) * | 2020-05-27 | 2023-07-14 | 上海启讯医药科技有限公司 | 一种多替拉韦关键中间体溶剂化物多晶型物及其制备方法和用途 |
| EP4249077A1 (en) | 2020-11-17 | 2023-09-27 | Shionogi & Co., Ltd | Novel acridinium salt and method for producing same |
| CN112480007B (zh) * | 2020-12-08 | 2022-11-18 | 宿迁市科莱博生物化学有限公司 | 一种1，3-二甲基-1h-吡唑-4-羧酸的合成方法 |
| EP4321217A3 (en) | 2021-01-19 | 2024-04-10 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
| CN115572257B (zh) * | 2021-06-21 | 2024-07-09 | 江西帝劢药业有限公司 | 一种吡啶酮类化合物的合成方法 |
| WO2023175386A2 (en) * | 2021-10-08 | 2023-09-21 | Laurus Labs Limited | Processes for preparation of cabotegravir or its pharmaceutically acceptable salts thereof |
| TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4769380A (en) | 1983-04-29 | 1988-09-06 | Merrell Dow Pharmaceuticals Inc. | Cardiotonic 5-benzoyl-1,2-dihydro-2-oxo-3-pyridinecarboxylates |
| JP4436229B2 (ja) | 2004-10-20 | 2010-03-24 | 株式会社沖データ | 電子装置 |
| US7858788B2 (en) | 2005-02-21 | 2010-12-28 | Shionogi & Co., Ltd. | Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
| EA014162B1 (ru) * | 2005-04-28 | 2010-10-29 | Смитклайн Бичем Корпорейшн | Полициклическое карбамоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич |
| UA96568C2 (en) * | 2005-04-28 | 2011-11-25 | Глаксосмиткляйн Ллк | Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor |
| JP5297105B2 (ja) | 2008-07-04 | 2013-09-25 | 株式会社クボタ | 乗用型田植機 |
| JP4975690B2 (ja) | 2008-07-07 | 2012-07-11 | アルファフーズ株式会社 | レトルト食品の製造方法 |
| WO2010011819A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| SI2320908T1 (sl) * | 2008-07-25 | 2014-05-30 | Viiv Healthcare Company | Predzdravila dolutegravirja |
| JP2010068253A (ja) | 2008-09-10 | 2010-03-25 | Sony Corp | 暗号処理装置 |
| JP2010068262A (ja) | 2008-09-11 | 2010-03-25 | New Japan Radio Co Ltd | 電子ボリウム |
| JP2010067176A (ja) | 2008-09-12 | 2010-03-25 | Nec Corp | 情報処理装置 |
| KR101663222B1 (ko) | 2008-12-11 | 2016-10-06 | 시오노기세야쿠 가부시키가이샤 | 말톨 에테르 방법 및 중간체 |
| MX2011006241A (es) | 2008-12-11 | 2011-06-28 | Shionogi & Co | Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios. |
| PT2376453T (pt) * | 2008-12-11 | 2020-01-14 | Shionogi & Co | Processos e intermediários para inibidores carbamoilpiridona da integrase de vih |
| TWI518084B (zh) * | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| TWI582097B (zh) * | 2010-03-23 | 2017-05-11 | Ｖｉｉｖ醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
| CN103154004B (zh) * | 2010-08-05 | 2016-07-06 | 盐野义制药株式会社 | 具有hiv整合酶抑制活性的化合物的制造方法 |
-
2011
- 2011-08-04 CN CN201180048343.XA patent/CN103154004B/zh active Active
- 2011-08-04 EP EP16190894.2A patent/EP3127908B1/en active Active
- 2011-08-04 LT LTEP18203589.9T patent/LT3456721T/lt unknown
- 2011-08-04 ES ES11814690.1T patent/ES2608377T3/es active Active
- 2011-08-04 BR BR112013002461A patent/BR112013002461A2/pt not_active Application Discontinuation
- 2011-08-04 JP JP2012527760A patent/JP5636054B2/ja active Active
- 2011-08-04 RS RS20210566A patent/RS61796B1/sr unknown
- 2011-08-04 SG SG2013008057A patent/SG187683A1/en unknown
- 2011-08-04 ES ES18203589T patent/ES2870006T3/es active Active
- 2011-08-04 ES ES16190894T patent/ES2710609T3/es active Active
- 2011-08-04 EP EP18203589.9A patent/EP3456721B1/en active Active
- 2011-08-04 HU HUE18203589A patent/HUE054473T2/hu unknown
- 2011-08-04 PL PL18203589T patent/PL3456721T3/pl unknown
- 2011-08-04 CN CN201610447148.9A patent/CN106083891B/zh active Active
- 2011-08-04 PT PT118146901T patent/PT2602260T/pt unknown
- 2011-08-04 DK DK18203589.9T patent/DK3456721T3/da active
- 2011-08-04 EP EP11814690.1A patent/EP2602260B1/en active Active
- 2011-08-04 PT PT16190894T patent/PT3127908T/pt unknown
- 2011-08-04 CN CN201610447110.1A patent/CN106046022B/zh active Active
- 2011-08-04 WO PCT/JP2011/067832 patent/WO2012018065A1/ja active Application Filing
- 2011-08-04 US US13/814,333 patent/US20140011995A1/en not_active Abandoned
- 2011-08-04 SI SI201131966T patent/SI3456721T1/sl unknown
- 2011-08-04 PT PT182035899T patent/PT3456721T/pt unknown
- 2011-08-05 TW TW100127858A patent/TWI510451B/zh active
-
2014
- 2014-10-20 US US14/518,209 patent/US9321789B2/en active Active
-
2016
- 2016-03-17 US US15/072,388 patent/US9650394B2/en active Active
-
2017
- 2017-03-28 US US15/471,133 patent/US9802959B2/en active Active
- 2017-09-20 US US15/709,742 patent/US9969750B2/en active Active
- 2017-09-20 US US15/709,728 patent/US10125147B2/en active Active
- 2017-09-20 US US15/709,716 patent/US10125146B2/en active Active
- 2017-09-20 US US15/709,701 patent/US10000508B2/en active Active
-
2021
- 2021-05-12 HR HRP20210748TT patent/HRP20210748T1/hr unknown
- 2021-05-17 CY CY20211100423T patent/CY1124582T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3456721T (lt) | Junginių, pasižyminčių živ integrazės inhibavimo aktyvumu, gavimo būdas | |
| IL268953B (en) | A process to form cycloalkylcarboxamido indole compounds | |
| HK1197400A1 (zh) | 治療 的化合物 | |
| ZA201303568B (en) | Method of producing a ppi-containing pharmaceutical preparation | |
| EP2609120A4 (en) | IMPROVED PROCESS FOR PREPARING SUGAMMADEX | |
| IL248217B (en) | A method for the production of inganol-3-englate | |
| EP2745235A4 (en) | METHOD FOR REPOSITIONING MEDICATION | |
| GB201004876D0 (en) | Process for the preparation of vitamin K2 | |
| HK1184787A1 (en) | Production method of intermediate compound for synthesizing medicament | |
| EP2552915A4 (en) | COMPOUNDS AND METHODS FOR THE TREATMENT OF HIV | |
| HUP1000638A2 (en) | Process for preparation of rosuvastatin salts | |
| HK1186172A1 (zh) | 製備 -氟- -羥基亞甲基－ -氧代丁酸酯的烯醇鹽方法 | |
| ZA201300083B (en) | New drug combinations for the treatment of malaria | |
| HK1171020A1 (en) | Process for preparation of pyrimidinylpyrazole compounds | |
| EP2537851A4 (en) | PROCESS FOR PREPARING B-GLYCOSIDE COMPOUNDS | |
| HK1201062A1 (en) | Process for the preparation of a statin precursor | |
| GB201019078D0 (en) | Process for the preparation of rosuvastatin | |
| AU2011905331A0 (en) | Treatment of seborrhoea | |
| PL391571A1 (pl) | Sposób otrzymywania katalizatorów oksyalkilenowania | |
| EP2593120A4 (en) | METHOD FOR THE TREATMENT OF HIV OR AIDS | |
| HUP1000616A2 (en) | Process for preparation of rosuvastatin salt | |
| TWM386114U (en) | Improved structure of punch former | |
| EP2546235A4 (en) | PROCESS FOR THE PREPARATION OF t-BUTOXYCARBONYLAMINE COMPOUNDS |